Abstract

Retrospective Study

Radiomics by Quantitative Diffusion-weighted MRI for Predicting Response in Patients with Extremity Soft-tissue Undifferentiated Pleomorphic Sarcoma

RF Valenzuela*, E Duran-Sierra, M Canjirathinkal, B Amini, KE Torres, RS Benjamin, J Ma, WL Wang, KP Hwang, RJ Stafford, C Wu, AM Zarzour, AJ Bishop, S Lo, JE Madewell, R Kumar, WA Murphy Jr and CM Costelloe

Published: 09 July, 2024 | Volume 8 - Issue 2 | Pages: 064-071

Purpose: This study aimed to determine the relevance of first- and high-order radiomic features derived from Diffusion-Weighted Imaging (DWI) and Apparent Diffusion Coefficient (ADC) maps for predicting treatment response in patients with Undifferentiated Pleomorphic Sarcoma (UPS).
Methods: This retrospective study included 33 extremity UPS patients with pre-surgical DWI/ADC and surgical resection. Manual volumetric tumor segmentation was performed on DWI/ADC maps acquired at Baseline (BL), Post-Chemotherapy (PC), and Post-Radiation Therapy (PRT). The percentage of pathology-assessed treatment effect (PATE) in surgical specimens categorized patients into responders (R; PATE ≥ 90%; 16 patients), partial-responders (PR; 89% - 31% PATE; 10 patients), and non-responders (NR; PATE ≤ 30%; 7 patients). 107 radiomic features were extracted from BL, PC, and PRT ADC maps. Statistical analyses compared R vs. PR/NR.
Results: Pseudo-progression at PC and universal stability at PRT were observed in R and PR/NR based on RECIST, WHO, and volumetric assessments. At PRT, responders displayed a 35% increase in ADC mean (p = 0.0034), a 136% decrease in skewness (p = 0.0001), and a 363% increase in the 90th percentile proportion (p = 0.0009). Comparing R vs. PR/NR at BL, statistically significant differences were observed in glrlm_highgraylevelrunemphasis (p = 0.0081), glrlm_shortrunhighgraylevelemphasis (p = 0.0138), gldm_highgraylevelemphasis (p = 0.0138), glcm_sumaverage (p = 0.0164), glcm_jointaverage (p = 0.0164), and glcm_autocorrelation (p = 0.0193). At PC, firstorder_meanabsolutedeviation (p = 0.0078), firstorder_interquartilerange (p = 0.0109), firstorder_variance (p = 0.0109),    and firstorder_robustmeanabsolutedeviation (p = 0.0151) provided statistically significant differences.
Conclusion: Observing a high post-therapeutic ADC mean, low skewness, and high 90th percentile proportion with respect to baseline is predictive of successfully treated UPS patients presenting > 90% PATE. Highly significant higher-order radiomic results include glrlm-highgraylevelrunemphasis (BL) and first-order-mean absolute deviation (PC).

Read Full Article HTML DOI: 10.29328/journal.jro.1001066 Cite this Article Read Full Article PDF

Keywords:

Apparent Diffusion Coefficient (ADC); Radiomics; Soft Tissue Sarcoma (STS); Undifferentiated Pleomorphic Sarcoma (UPS); Pathology-Assessed Treatment Effect (PATE)

References

  1. DeLaney TF, et al. Soft tissue sarcomas, in Treatment of cancer. 2020; 434-458.
  2. Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine. CA Cancer J Clin. 2020;70(3):200-229. Available from: https://pubmed.ncbi.nlm.nih.gov/32275330/
  3. Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives. Pathologica. 2021;113(2):70-84. Available from: https://pubmed.ncbi.nlm.nih.gov/33179614/
  4. Robles-Tenorio A, Solis-Ledesma G. Undifferentiated Pleomorphic Sarcoma. 2023 Apr 10. In: StatPearls [Internet]. Treasure Island (FL): 2024; 34033374. Available from: https://pubmed.ncbi.nlm.nih.gov/34033374/
  5. Valenzuela RF, Amini B, Duran-Sierra E, Canjirathinkal MA, Madewell JE, Costelloe CM, et al. Multiparametric MRI for the Assessment of Treatment Effect and Tumor Recurrence in Soft-tissue Sarcoma of the Extremities. J Radiol Oncol. 2023;7(3):058-065. Available from: https://www.radiooncologyjournal.com/articles/jro-aid1055.php
  6. Jo VY, Fletcher CD. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology. 2014;46(2):95-104. Available from: https://pubmed.ncbi.nlm.nih.gov/24378391/
  7. Roberge D, Skamene T, Nahal A, Turcotte RE, Powell T, Freeman C. Radiological and pathological response following pre-operative radiotherapy for soft-tissue sarcoma. Radiother Oncol. 2010;97(3):404-7. Available from: https://pubmed.ncbi.nlm.nih.gov/21040989/
  8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47. Available from: https://pubmed.ncbi.nlm.nih.gov/19097774/
  9. Valenzuela RF, Kundra V, Madewell JE, Costelloe CM. Advanced Imaging in Musculoskeletal Oncology: Moving Away From RECIST and Embracing Advanced Bone and Soft Tissue Tumor Imaging (ABASTI) - Part I - Tumor Response Criteria and Established Functional Imaging Techniques. Semin Ultrasound CT MR. 2021;42(2):201-214. Available from: https://pubmed.ncbi.nlm.nih.gov/33814106/
  10. Wardelmann E, Haas RL, Bovée JV, Terrier P, Lazar A, Messiou C, et al. Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting. Eur J Cancer. 2016;53:84-95. Available from: https://pubmed.ncbi.nlm.nih.gov/26700077/
  11. Soldatos T, Ahlawat S, Montgomery E, Chalian M, Jacobs MA, Fayad LM. Multiparametric Assessment of Treatment Response in High-Grade Soft-Tissue Sarcomas with Anatomic and Functional MR Imaging Sequences. Radiology. 2016;278(3):831-40. Available from: https://pubmed.ncbi.nlm.nih.gov/26390048/
  12. Subhawong TK, Wilky BA. Value added: functional MR imaging in management of bone and soft tissue sarcomas. Curr Opin Oncol. 2015;27(4):323-31. Available from: https://pubmed.ncbi.nlm.nih.gov/26049272/
  13. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol. 2007;188(6):1622-35. Available from: https://pubmed.ncbi.nlm.nih.gov/17515386/
  14. Einarsdóttir H, Karlsson M, Wejde J, Bauer HC. Diffusion-weighted MRI of soft tissue tumours. Eur Radiol. 2004;14(6):959-63. Available from: https://pubmed.ncbi.nlm.nih.gov/14767604/
  15. Halefoglu AM, Yousem DM. Susceptibility weighted imaging: Clinical applications and future directions. World J Radiol. 2018;10(4):30-45. Available from: https://pubmed.ncbi.nlm.nih.gov/29849962/
  16. Martín-Noguerol T, Montesinos P, Casado-Verdugo OL, Beltrán LS, Luna A. Susceptibility Weighted Imaging for evaluation of musculoskeletal lesions. Eur J Radiol. 2021;138:109611. Available from: https://pubmed.ncbi.nlm.nih.gov/33677418/
  17. Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging. 2002;16(4):407-22. Available from: https://pubmed.ncbi.nlm.nih.gov/12353256/
  18. Huang W, Beckett BR, Tudorica A, Meyer JM, Afzal A, Chen Y, et al. Evaluation of Soft Tissue Sarcoma Response to Preoperative Chemoradiotherapy Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Tomography. 2016;2(4):308-316. Available from: https://pubmed.ncbi.nlm.nih.gov/28066805/
  19. Messina C, Bignone R, Bruno A, Bruno A, Bruno F, Calandri M, et al. Diffusion-Weighted Imaging in Oncology: An Update. Cancers (Basel). 2020;12(6):1493. Available from: https://pubmed.ncbi.nlm.nih.gov/32521645/
  20. Bammer R. Basic principles of diffusion-weighted imaging. Eur J Radiol. 2003;45(3):169-84. Available from: https://pubmed.ncbi.nlm.nih.gov/12595101/
  21. Le Bihan D. Apparent diffusion coefficient and beyond: what diffusion MR imaging can tell us about tissue structure. Radiology. 2013;268(2):318-22. Available from: https://pubmed.ncbi.nlm.nih.gov/23882093/
  22. Lee JH, Yoon YC, Seo SW, Choi YL, Kim HS. Soft tissue sarcoma: DWI and DCE-MRI parameters correlate with Ki-67 labeling index. Eur Radiol. 2020;30(2):914-924. Available from: https://pubmed.ncbi.nlm.nih.gov/31630234/
  23. Sierra ED, Valenzuela R, Canjirathinkal MA, Costelloe CM, Moradi H, Madewell JE, et al. Cancer Radiomic and Perfusion Imaging Automated Framework: Validation on Musculoskeletal Tumors. JCO Clin Cancer Inform. 2024;8:e2300118. Available from: https://pubmed.ncbi.nlm.nih.gov/38181324/
  24. Duran-Sierra EVR, Canjirathinkal M, Murphy W, Madewell J, Costelloe C, Amini B. Apparent Diffusion Coefficient (ADC) High-Order Radiomics of Baseline and Post-treatment Advanced MRI of extremity Soft-Tissue Undifferentiated Pleomorphic Sarcoma, in ECR 2023. 2023.
  25. Drapé JL. Advances in magnetic resonance imaging of musculoskeletal tumours. Orthop Traumatol Surg Res. 2013;99(1 Suppl):S115-23. Available from: https://pubmed.ncbi.nlm.nih.gov/23380432/
  26. Dudeck O, Zeile M, Pink D, Pech M, Tunn PU, Reichardt P, et al. Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J Magn Reson Imaging. 2008;27(5):1109-13. Available from: https://pubmed.ncbi.nlm.nih.gov/18425832/
  27. Winfield JM, Miah AB, Strauss D, Thway K, Collins DJ, deSouza NM, et al. Utility of Multi-Parametric Quantitative Magnetic Resonance Imaging for Characterization and Radiotherapy Response Assessment in Soft-Tissue Sarcomas and Correlation With Histopathology. Front Oncol. 2019;9:280. Available from: https://pubmed.ncbi.nlm.nih.gov/31106141/
  28. Law MY, Liu B. Informatics in radiology: DICOM-RT and its utilization in radiation therapy. Radiographics. 2009;29(3):655-67. Available from: https://pubmed.ncbi.nlm.nih.gov/19270073/
  29. van Timmeren JE, Cester D, Tanadini-Lang S, Alkadhi H, Baessler B. Radiomics in medical imaging-"how-to" guide and critical reflection. Insights Imaging. 2020;11(1):91. Available from: https://pubmed.ncbi.nlm.nih.gov/32785796/
  30. van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, et al. Computational Radiomics System to Decode the Radiographic Phenotype. Cancer Res. 2017;77(21):e104-e107. Available from: https://pubmed.ncbi.nlm.nih.gov/29092951/
  31. Subhawong TK, Feister K, Sweet K, Alperin N, Kwon D, Rosenberg A, et al. MRI Volumetrics and Image Texture Analysis in Assessing Systemic Treatment Response in Extra-Abdominal Desmoid Fibromatosis. Radiol Imaging Cancer. 2021;3(4):e210016. Available from: https://pubmed.ncbi.nlm.nih.gov/34213370/
  32. Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D, et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat Methods. 2020;17(3):261-272. Epub 2020 Feb 3. Erratum in: Nat Methods. 2020;17(3):352. Available from: https://pubmed.ncbi.nlm.nih.gov/32015543/
  33. Nishino M, Hatabu H, Hodi FS. Imaging of Cancer Immunotherapy: Current Approaches and Future Directions. Radiology. 2019;290(1):9-22. Available from: https://pubmed.ncbi.nlm.nih.gov/30457485/
  34. Fields BKK, Hwang D, Cen S, Desai B, Gulati M, Hu J, Duddalwar V, Varghese B, Matcuk GR Jr. Quantitative magnetic resonance imaging (q-MRI) for the assessment of soft-tissue sarcoma treatment response: a narrative case review of technique development. Clin Imaging. 2020;63:83-93. Available from: https://pubmed.ncbi.nlm.nih.gov/32163847/
  35. Miki Y, Ngan S, Clark JC, Akiyama T, Choong PF. The significance of size change of soft tissue sarcoma during preoperative radiotherapy. Eur J Surg Oncol. 2010;36(7):678-83. Available from: https://pubmed.ncbi.nlm.nih.gov/20547446/

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?